Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Construction of IMMS Containing Multi-site Liposomes for Dynamic Monitoring of Blood CTC in Patients with Osimertinib-resistant Non-small-cell Lung Cancer and its Mechanism

Author(s): Xiaoju Chen, Ling Luo, Yanyan Lu, Ye Qiu, Jie Liang, Yulin Chen, Yufang Ning and Bixun Li*

Volume 23, Issue 6, 2023

Published on: 08 December, 2022

Page: [676 - 686] Pages: 11

DOI: 10.2174/1871520623666221107140624

Price: $65

Abstract

Objective: This article aims to establish a liquid biopsy system for gene detection of circulating tumor cells (CTC) in lung cancer, systematically analyze the significance of osimertinib resistance, and formulate an individualized diagnosis and treatment plan.

Methods: Liposome-contained magnetic microspheres coated with Fe3O4 nanoparticles were synthesized by microemulsion, and the surface was modified with EGFR antibody to form EGFR/EpCAM multi-site liposome-contained immunomagnetic microspheres (IMMSs). The CTCs were isolated and identified from peripheral blood samples and the cell lines of lung cancer patients collected by the multi-site liposome-contained IMMSs. To investigate the effects of the order of use of IMMSs sequence at different sites on the sorting and trapping efficiency of non-small-cell lung cancer (NSCLC) cells . The preliminary verification of drug-resistant gene function and dynamic monitoring of CTCs in 20 patients with EGFR-positive NSCLC were screened and statistically analyzed before and after osimertinib treatment. Sensitivity analysis and drug resistance evaluation of oxitidine were detected in vitro.

Results: Results showed the prepared multi-site liposome-contained IMMSs had high stability and specificity. The number of CTCs in blood samples of the patients with NSCLC was detected, revealing high sorting efficiency, and positive sorting rate reaching more than 90%. We investigated the effect of osimertinib on the HER-2 expression on the EGFR-mutated NSCLC cells and found that osimertinib increased the expression of HER-2 on the cell surface of NSCLC cell lines., And further explored the therapeutic potential of osimertinib combined with T-DM1 at different dosing times.

Conclusion: Our results demonstrate that the prepared multi-site liposome-contained IMMSs can efficiently isolate CTCs from the peripheral blood in lung cancer. Combined with the experimental data about osimertinib can be effectively identified, the resistant genes of NSCLC including EGFR, which will provide a new scientific basis for guiding clinical medication and formulating individualized treatment plans.

« Previous Next »
Graphical Abstract

[1]
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, 136(5), E359-E386.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[2]
Nanavaty, P.; Alvarez, M.S.; Michael, W. Lung cancer screening: Advantages, controversies, and applications. Univ Calgary, 2014, 21(1), 9-14.
[3]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. CA Cancer J. Clin., 2018, 68(1), 7-30.
[4]
Santarpia, M.; Karachaliou, N.; Rosell, R. Beyond platinum treatment for NSCLC: What does the future hold? Expert Rev. Anticancer Ther., 2017, 17(4), 293-295.
[http://dx.doi.org/10.1080/14737140.2017.1288103] [PMID: 28129003]
[5]
Zhang, Y.L.; Yuan, J.Q.; Wang, K.F.; Fu, X.H.; Han, X.R.; Threapleton, D.; Yang, Z.Y.; Mao, C.; Tang, J.L. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget, 2016, 7(48), 78985-78993.
[http://dx.doi.org/10.18632/oncotarget.12587] [PMID: 27738317]
[6]
NCCN. NCCN Clinical Practice Guidelines in Oncology NSCLC (version 7.2015). 2015.
[7]
Masters, G.A.; Temin, S.; Azzoli, C.G.; Giaccone, G.; Baker, S., Jr; Brahmer, J.R.; Ellis, P.M.; Gajra, A.; Rackear, N.; Schiller, J.H.; Smith, T.J.; Strawn, J.R.; Trent, D.; Johnson, D.H. Systemic therapy for Stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J. Clin. Oncol., 2015, 33(30), 3488-3515. epub ahead of print
[http://dx.doi.org/10.1200/JCO.2015.62.1342] [PMID: 26324367]
[8]
Nathan, A. Pennell, Maria E Arcila, David R Gandara. Howard west biomarker testing for patients with advanced non-small cell lung cancer: Real-world issues and tough choices. Am. Soc. Clin. Oncol. Educ. Book, 2019, 39, 531-542.
[9]
Brown, S.; Banfill, K.; Marianne, C. The evolving role of radiotherapy in non-small cell lung cancer. Br. J. Radiol., 2019, 92(1104)20190524
[10]
Jonna, S.; Subramaniam, D.S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): An update. Discov. Med., 2019, 27(148), 167-170.
[11]
Reck, M.; Borghaei, H.; Kenneth, J.B. Nivolumab plus ipilimumab in non-small-cell lung cancer. N. Engl. J. Med., 2019, 15(19), 2287-2302.
[12]
Remark, R.; Becker, C.; Gomez, J.E. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am. J. Respir. Crit. Care Med., 2015, 191(4), 377-390.
[13]
Cross, D.A.E.; Ashton, S.E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C.A.; Spitzler, P.J.; Orme, J.P.; Finlay, M.R.V.; Ward, R.A.; Mellor, M.J.; Hughes, G.; Rahi, A.; Jacobs, V.N.; Brewer, M.R.; Ichihara, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G.H.P.; Cantarini, M.; Kim, D.W.; Ranson, M.R.; Pao, W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov., 2014, 4(9), 1046-1061.
[http://dx.doi.org/10.1158/2159-8290.CD-14-0337] [PMID: 24893891]
[14]
Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.M.E.; Lee, C.K.; Sebastian, M.; Templeton, A.; Mann, H.; Marotti, M.; Ghiorghiu, S.; Papadimitrakopoulou, V.A. Osimertinib or platinum-pemetrexed in EGFR T790M–positive lung cancer. N. Engl. J. Med., 2017, 376(7), 629-640.
[http://dx.doi.org/10.1056/NEJMoa1612674] [PMID: 27959700]
[15]
Soria, J.C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B.C.; Cheng, Y.; Cho, E.K.; Voon, P.J.; Planchard, D.; Su, W.C.; Gray, J.E.; Lee, S.M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S.S. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med., 2018, 378(2), 113-125.
[http://dx.doi.org/10.1056/NEJMoa1713137] [PMID: 29151359]
[16]
Lamb, Y.N. Osimertinib: A review in previously untreated, EGFR mutation-positive, advanced NSCLC. Target. Oncol., 2021, 16(5), 687-695.
[http://dx.doi.org/10.1007/s11523-021-00839-w] [PMID: 34564820]
[17]
Oxnard, G.R.; Hu, Y.; Mileham, K.F.; Husain, H.; Costa, D.B.; Tracy, P.; Feeney, N.; Sholl, L.M.; Dahlberg, S.E.; Redig, A.J.; Kwiatkowski, D.J.; Rabin, M.S.; Paweletz, C.P.; Thress, K.S.; Jänne, P.A. Assessment of resistance mechanisms and clinical implications in patients with egfr t790m-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol., 2018, 4(11), 1527-1534.
[http://dx.doi.org/10.1001/jamaoncol.2018.2969] [PMID: 30073261]
[18]
Santarpia, M.; Gil, N.; Rosell, R. Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Expert Rev. Clin. Pharmacol., 2015, 8(4), 461-477.
[http://dx.doi.org/10.1586/17512433.2015.1055252] [PMID: 26068305]
[19]
Labib, Mahmoud Kelley, S.O. Circulating tumor cell profiling for precision oncology. 2021, 15(6), 1622-1646.
[20]
Santarpia, M.; Karachaliou, N.; González-Cao, M.; Altavilla, G.; Giovannetti, E.; Rosell, R. Feasibility of cell-free circulating tumor DNA testing for lung cancer. Biomarkers Med., 2016, 10(4), 417-430.
[http://dx.doi.org/10.2217/bmm.16.6] [PMID: 26974841]
[21]
Vassiliki, A; Ji-Youn, H. Myung-Ju, A Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation- positive advanced non-small cell lung cancer. 2020, 126(2), 373-380.
[22]
Oxnard, G.R.; Paweletz, C.P.; Kuang, Y.; Mach, S.L.; O’Connell, A.; Messineo, M.M.; Luke, J.J.; Butaney, M.; Kirschmeier, P.; Jackman, D.M.; Jänne, P.A. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res., 2014, 20(6), 1698-1705.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-2482] [PMID: 24429876]
[23]
Sundaresan, T.K.; Sequist, L.V.; Heymach, J.V.; Riely, G.J.; Jänne, P.A.; Koch, W.H.; Sullivan, J.P.; Fox, D.B.; Maher, R.; Muzikansky, A.; Webb, A.; Tran, H.T.; Giri, U.; Fleisher, M.; Yu, H.A.; Wei, W.; Johnson, B.E.; Barber, T.A.; Walsh, J.R.; Engelman, J.A.; Stott, S.L.; Kapur, R.; Maheswaran, S.; Toner, M.; Haber, D.A. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin. Cancer Res., 2016, 22(5), 1103-1110.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1031] [PMID: 26446944]
[24]
Hunter, F.W.; Barker, H.R.; Lipert, B.; Rothé, F.; Gebhart, G.; Piccart-Gebhart, M.J.; Sotiriou, C.; Jamieson, S.M.F. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br. J. Cancer, 2020, 122(5), 603-612.
[http://dx.doi.org/10.1038/s41416-019-0635-y] [PMID: 31839676]
[25]
Mohammed, T.; Mangeshkar, S.; Desai, A. HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma. J. Oncol. Pharm. Pract., 2021, 27(7), 1806-1809.
[26]
Fanotto, V.; Ongaro, E.; Karim, R.; Antonio, A.; Nicola, S.; Lorenzo, F.; Enrico, V.; Lorenzo, A.; Francesco, L.; Gerardo, R.; Francesco, G.; Roberto, B.; Mario, S.; Giovanna, D.M.; Francesca, V.N.; Gianpiero, F.; Giuseppe, A. HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7(42), 69060-69074.
[27]
Mirza, S.; Hadi, N.; Pervaiz, S.; Sultan, Z.K.; Sameer, A.M.; Tariq, A.; Nawwaf, A.H.; Fahim, V. Expression of HER-2/neu in oral squamous cell carcinoma. 2020, 21(5), 1465-1470.
[28]
Jain, P.; Goyal, S.; Chauhan, G.; Kaushik, M.; Shahajad, A.; Puja, S.; Anil, K.A. HER-2/neu over expression in gall bladder adenocarcinoma: A quest for potential therapeutic target. Indian J. Pathol. Microbiol., 2020, 63(2), 214-220.
[29]
Leonetti, A.; Sharma, S.; Minari, R.; Paola, P.; Elisa, G.; Marcello, T. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer, 2019, 121(9), 725-737.
[30]
Remon, J.; Steuer, C.E.; Ramalingam, S.S.; Felip, E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann. Oncol., 2018, 29(Suppl. 1), i20-i27.
[31]
Hsu, C.C.; Liao, B.C.; Liao, W.Y.; Markovets, A.; Stetson, D.; Thress, K.; Yang, J.C. Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell. Lung Cancer, 2020, 15(1), 50-61.
[32]
Sun, P. QU, Y.; Wang, Y.; Wang, J.; Wang, X.; Sheng, J. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer. J. Cancer, 2021, 12(13), 3900-3908.
[33]
Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; Lee, C.K.; Sebastian, M.; Templeton, A.; Mann, H.; Marotti, M.; Ghiorghiu, S.; Papadimitrakopoulou, V.A. AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive. N. Engl. J. Med., 2017, 376(7), 629-640.
[34]
Papadimitrakopoulou, V.A.; Mok, T.S.; Han, J.Y.; Ahn, M.J.; Delmonte, A.; Ramalingam, S.S.; Kim, S.W.; Shepherd, F.A.; Laskin, J.; He, Y.; Akamatsu, H.; Theelen, W.S.M.E.; Su, W.C.; John, T.; Sebastian, M.; Mann, H.; Miranda, M.; Laus, G.; Rukazenkov, Y.; Wu, Y.L. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann. Oncol., 2020, 31(11), 1536-1544.
[35]
Hirano, T.; Yasuda, H.; Tani, T.; Hamamoto, J.; Oashi, A.; Ishioka, K.; Arai, D.; Nukaga, S.; Miyawaki, M.; Kawada, I.; Naoki, K.; Costa, D.B.; Kobayashi, S.S.; Betsuyaku, T.; Soejima, K. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget, 2015, 6(36), 38789-38803.
[http://dx.doi.org/10.18632/oncotarget.5887] [PMID: 26515464]
[36]
Ewer, M.S.; Tekumalla, S.H.; Walding, A.; Atuah, K.N. Cardiac safety of osimertinib: A review of data. J. Clin. Oncol., 2021, 39(4), 328-337.
[37]
Montemurro, F.; Delaloge, S.; Barrios, C.H.; Wuerstlein, R.; Anton, A.; Brain, E.; Hatschek, T.; Kelly, C.M.; Peña-Murillo, C.; Yilmaz, M.; Donica, M.; Ellis, P. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann. Oncol., 2020, 31(10), 1350-1358.
[38]
Nooreldeen, R.; Bach, H. Current and future development in lung cancer diagnosis. Int. J. Mol. Sci., 2021, 22(16), 8661.
[39]
Vasseur, A.; Kiavue, N.; Bidard, F.C.; Pierga, J.Y.; Cabel, L. Clinical utility of circulating tumor cells: An update. Mol. Oncol., 2021, 15(6), 1647-1666.
[40]
Micalizzi, D.S.; Maheswaran, S.; Haber, D.A. A conduit to metastasis: Circulating tumor cell biology. Genes Dev., 2017, 31(18), 1827-1840.
[http://dx.doi.org/10.1101/gad.305805.117] [PMID: 29051388]
[41]
Tayoun, T.; Faugeroux, V.; Oulhen, M.; Aberlenc, A.; Pawlikowska, P.; Farace, F. CTC-derived models: A window into the seeding capacity of Circulating Tumor Cells (CTCs). Cells, 2019, 8(10), 1145.
[42]
Yang, J.D.; Campion, M.B.; Liu, M.C.; Chaiteerakij, R.; Giama, N.H.; Ahmed Mohammed, H.; Zhang, X.; Hu, C.; Campion, V.L.; Jen, J.; Venkatesh, S.K.; Halling, K.C.; Kipp, B.R.; Roberts, L.R. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology, 2016, 63(1), 148-158.
[http://dx.doi.org/10.1002/hep.27944] [PMID: 26096702]
[43]
Robichaux, J.P.; Elamin, Y.Y.; Tan, Z.; Carter, B.W.; Zhang, S.; Liu, S.; Li, S.; Chen, T.; Poteete, A.; Estrada-Bernal, A.; Le, A.T.; Truini, A.; Nilsson, M.B.; Sun, H.; Roarty, E.; Goldberg, S.B.; Brahmer, J.R.; Altan, M.; Lu, C.; Papadimitrakopoulou, V.; Politi, K.; Doebele, R.C.; Wong, K.K.; Heymach, J.V. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat. Med., 2018, 24(5), 638-646.
[44]
Ramalingam, S.; Reungwetwattana, T.; Chewaskulyong, B.; Dechaphunkul, A.; Lee, K.H.; Imamura, F.; Nogami, N.; Ohe, Y.; Cheng, Y.; Cho, B.C.; Cho, E.K.; Vansteenkiste, J.F.; Voon, P.J.; Zhou, C.; Gray, J.; Hodge, R.; Rukazenkov, Y.; Soria, J-C. Osimertinib vs. standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Ann. Oncol., 2017, 28, v635.
[http://dx.doi.org/10.1093/annonc/mdx440.050]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy